Leopoldo Zambeletti

Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area. Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.

At LenioBio, we develop efficient, robust and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are. Unconstrained by the limitations of cells, we combine our proprietary protein technology with machine learning to significantly accelerate innovation cycles in life science industry.

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature’s greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area. Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.

Since it has been founded in 1985, Tema Sinergie has been dedicated to Design, Production and Service of shielded equipment and measuring instruments for a safe use of radioactive materials. Our main manufacturing activities are: PET equipment applications, Nuclear Medicine, Health Physics, Radiotherapy and Industrial Radiography. Since 1992 our company has been the Italian exclusive distributor for several world-wide leading and prestigious companies in the field of Radiotherapy, Diagnostic Radiology and Environmental Monitoring. Sinergie means a strict and cooperating interaction between produced and represented products, offering to customers a complete service according to their needs due to the high qualification of its personnel. Tema Sinergie counts more than 1,500 customers all over the world among which are included Hospitals, Universities, Research Centres and Industries.

At LenioBio, we develop efficient, robust and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are. Unconstrained by the limitations of cells, we combine our proprietary protein technology with machine learning to significantly accelerate innovation cycles in life science industry.

At Touchlight we are revolutionising DNA. Our Company and technology is built on the conviction that DNA is fundamental to the future of medicine. By moving away from todays restrictive biological approaches, we have made DNA simple. Our unique dbDNA™ (or "doggybone" DNA) vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA. The platform, based on enzymatic technology, enable DNA production at unprecedented scale, speed and purity. We are leveraging our platform to develop the next generation of DNA vaccines for oncology and infectious diseases, in house and in collaboration with industry partners and academics, as well as enabling manufacture of advanced therapies (viral vectors, mRNA vaccines, and cell therapies) through our CDMO, Touchlight DNA Services. For more information please visit our website or get in touch by emailing info@touchlight.com.